Macquarie Group Ltd. Has $15.49 Million Position in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Macquarie Group Ltd. lifted its position in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 35.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 356,202 shares of the biopharmaceutical company’s stock after acquiring an additional 93,625 shares during the quarter. Macquarie Group Ltd. owned 0.70% of Ultragenyx Pharmaceutical worth $15,487,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 12.5% during the 4th quarter. Geode Capital Management LLC now owns 568,230 shares of the biopharmaceutical company’s stock valued at $24,706,000 after buying an additional 63,118 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Ultragenyx Pharmaceutical by 5.3% during the 3rd quarter. Wells Fargo & Company MN now owns 23,742 shares of the biopharmaceutical company’s stock valued at $1,812,000 after buying an additional 1,194 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Ultragenyx Pharmaceutical by 4.0% during the 4th quarter. California State Teachers Retirement System now owns 74,783 shares of the biopharmaceutical company’s stock valued at $3,252,000 after buying an additional 2,851 shares in the last quarter. Jane Street Group LLC bought a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $1,954,000. Finally, Kiwi Wealth Investments Limited Partnership bought a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $958,000. Hedge funds and other institutional investors own 98.62% of the company’s stock.

Several equities research analysts have recently commented on the stock. Morgan Stanley upgraded shares of Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $68.00 to $83.00 in a report on Wednesday, March 27th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $73.00 price target for the company in a report on Tuesday. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. SunTrust Banks boosted their price target on shares of Ultragenyx Pharmaceutical to $71.00 and gave the company a “buy” rating in a report on Wednesday, January 23rd. Finally, Raymond James downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 2nd. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $78.39.

NASDAQ:RARE traded down $0.06 during trading hours on Wednesday, hitting $67.73. 258,235 shares of the company were exchanged, compared to its average volume of 634,632. The company has a market cap of $3.49 billion, a PE ratio of -9.17 and a beta of 2.22. Ultragenyx Pharmaceutical Inc has a 52-week low of $37.44 and a 52-week high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, topping the consensus estimate of ($1.74) by $0.01. The company had revenue of $16.26 million for the quarter, compared to the consensus estimate of $13.30 million. Ultragenyx Pharmaceutical had a negative net margin of 383.75% and a negative return on equity of 35.26%. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc will post -6.65 earnings per share for the current fiscal year.

In other news, CFO Shalini Sharp sold 14,800 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $70.00, for a total value of $1,036,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.40% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/macquarie-group-ltd-increases-position-in-ultragenyx-pharmaceutical-inc-rare.html.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Article: Investing strategies using the yield curve

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.